Cas13 Guide RNA Targeting for Mutating SARS Viral RNA
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies face challenges in effectively screening, treating, and preventing SARS and COVID-related diseases due to the genetic mutations of SARS-COV-1 and SARS-COV-2 viruses, making it difficult to develop targeted therapies.
Innovation Solution
Development of synthetic guide RNAs that bind to SARS-COV-1 and SARS-COV-2 nucleocapsid or replicase sequences, combined with Cas13 molecules, delivered via lipid nanoparticles, to target and degrade viral RNA, accompanied by a method for detection and treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional screening and treatment methods are used, then existing therapies can be applied, but they become ineffective due to genetic mutations of SARS-COV-1 and SARS-COV-2 viruses
Solution Approach 1:
The guide RNA is designed with a structure that includes both a CRISPR repeat region for Cas13 binding and a variable target sequence region. This universal design allows the same Cas13 system to be adapted to target different viral strains by simply changing the guide RNA sequence, making the system versatile against multiple SARS coronavirus variants while maintaining reliable viral RNA degradation functionality
Solution Approach 2:
The invention changes the nucleotide sequence parameters of the guide RNA to match different viral genetic mutations. By adjusting the target sequence region of the guide RNA to complement different viral RNA sequences, the system maintains effectiveness against genetically diverse SARS-COV-1 and SARS-COV-2 strains
2Reliability
If targeted therapies are developed, then treatment effectiveness improves, but it becomes difficult to screen for new strains due to continuous viral evolution
Solution Approach 1:
The system performs preliminary detection by using the guide RNA to specifically bind to viral RNA sequences before treatment is administered. This preliminary screening action identifies the presence of specific viral strains, allowing for targeted therapy selection while accounting for genetic variations
Solution Approach 2:
The guide RNA acts as an intermediary between the Cas13 enzyme and the viral RNA. It mediates the specific recognition and binding to different viral sequences, enabling both detection and targeted degradation. This intermediary approach allows the same Cas13 system to adapt to new strains through guide RNA sequence changes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The guide RNAs and Cas13 system effectively reduce viral load and facilitate detection of SARS-COV-1 and SARS-COV-2 infections, providing a therapeutic and preventive approach.
Implementation Method 1
a guide RNA comprising SEQ ID NO: 5 or SEQ ID NO: 6 joined to a second nucleotide sequence that is complementary to SARS-COV-1 and SARS-COV-2
Implementation Method 2
a method of treating or preventing a SARS-COV-1 or a SARS-COV-2 infection in a subject, the method comprising administering a therapeutically effective amount of at least one synthetic guide RNAs of any preceding aspect, a Cas13
Implementation Method 3
Development of synthetic guide RNAs that bind to SARS-COV-1 and SARS-COV-2 nucleocapsid or replicase sequences, combined with Cas13 molecules, delivered via lipid nanoparticles
Data Source
AI summary
The present disclosure relates to anti-SARS-COV-1 and anti-SARS-COV-2 activatable RNase guide sequences and methods of use for screening, treating, and/or preventing SARS infections and/or COVID-related diseases.